EUDA Health Holdings Limited — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; unaudited, U.S. GAAP. EUDA operates medical services and property management businesses, primarily in Singapore. The company completed its reverse recapitalization in November 2022.
Financial performance
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Revenue | $1.70 million | $2.67 million | Down 36.3% |
| Gross profit / margin | $404,000 / 23.8% | $1.27 million / 47.7% | Margin down 23.9 percentage points |
| Operating income (loss) | $(1.98) million | $75,000 | Turned to loss |
| Net income (loss) | $(2.41) million | $225,000 | Turned to loss |
| Net income (loss) attributable to EUDA | $(2.41) million | $223,000 | Turned to loss |
| Operating cash flow | $(470,000) | $(252,000) | Cash use increased |
- Medical-services revenue fell 49.2% to $792,000. Management cited fewer corporate clients (about 370 versus 400) and lower patient utilization (993 versus 1,300).
- Property-management revenue declined 17.7% to $907,000 as managed properties decreased. Product-sales revenue was zero.
- Medical-services gross margin contracted to 23.3% from 64.5%, which management attributed mainly to higher third-party provider prices after moving away from a related-party provider. Property-management gross margin was 24.2%, essentially flat year over year.
- Operating expenses increased 99.0% to $2.38 million, mainly from higher professional fees included in general and administrative expense. Other expense included a $532,000 fair-value loss on prepaid forward purchase liabilities.
Financial position and liquidity
- At March 31, 2023, cash was $837,000; restricted cash was zero. Current assets were $24.80 million and current liabilities $31.33 million, producing a working-capital deficit of approximately $6.5 million. Total liabilities were $31.42 million; shareholders’ deficit was $5.94 million.
- Current liabilities included $20.85 million of prepaid forward purchase liabilities, $2.62 million of third-party convertible notes, $783,000 of related-party convertible notes, $320,000 of bank/private loans, $274,000 of related-party short-term loans, and a $170,000 promissory note. Related-party payables were $1.67 million.
- Financing activities provided $525,000 in Q1, principally through short-term borrowings and related-party funding. Cash increased by $53,000 over the quarter, despite operating cash use of $470,000.
- Management states recurring operating losses and negative operating cash flows since 2020, and concludes that substantial doubt exists about the company’s ability to continue as a going concern within one year after issuance. Management expects to pursue lender/private financing, related-party support, and equity financing; availability and acceptable terms are not assured.
Outlook, risks, contingencies, and unusual items
- No specific quarterly or annual operating forecast is provided. Management describes plans to grow corporate clients, expand healthcare services and digital capabilities, and pursue Southeast Asian markets. These plans depend on adoption, customer retention, competition, and funding.
- The filing describes contractual earnout thresholds for 2023 of $20.1 million revenue and $3.6 million net income, and for 2024 of $40.1 million revenue and $10.1 million net income. These are earnout conditions, not management guidance.
- After quarter-end, the company reported a $940,000 private placement at $1.00 per share and several debt settlements involving restricted shares, including conversion of a $700,000 related-party note into 700,000 shares and share settlements of other notes and obligations.
- On June 8, 2023, the company amended the prepaid forward agreements, accelerating maturity and providing for share settlement. The filing’s description refers to 800,000 shares and also to 1,600,000 shares in aggregate; the exact number and final accounting should be checked against the amendments. The agreements had been a major balance-sheet liability and generated a Q1 fair-value loss.
- Management identified ineffective disclosure controls due to insufficient U.S. GAAP/SEC-reporting personnel and inadequate processes for assessing third-party specialists. Remediation steps were planned; management had not yet deemed the weaknesses remediated.
- Management cites customer adoption and privacy concerns, competition, economic uncertainty, inflation and interest rates, reliance on key personnel, and the loss of the CTO in May 2023 as risks. It reported no material legal proceedings as of March 31, 2023; Singapore tax returns for 2019–2022 remained open for examination.
Important facts for investors to verify
- Whether subsequent financing and related-party support are sufficient to address the stated going-concern uncertainty and near-term obligations.
- The exact share consideration and accounting treatment under the June 8 prepaid-forward amendments; the filing text gives conflicting aggregate share counts.
- The final share count, pricing, registration status, and dilution effects of the post-quarter debt and related-party settlements and private placement.
- The drivers of declining medical utilization and property-management contracts, and whether medical-service margins can recover after higher provider costs.
- Reconcile the filing’s EPS detail: the income statement reports a $2,414,645 loss attributable to EUDA, while the EPS note reports $2,414,465.